Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Respiratory products
Please find a list of our respiratory products below.
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol inhalation powder)
Trelegy Ellipta (92/55/22 micrograms inhalation powder) is a combination of inhaled corticosteroid, long-acting muscarinic receptor antagonist and long-acting beta2-adrenergic agonist (ICS/LAMA/LABA) and is indicated for maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA or a combination of a LAMA and a LABA.
Anoro Ellipta (umeclidinium / vilanterol inhalation powder)
Anoro Ellipta (55 micrograms/22 micrograms inhalation powder) is a long-acting muscarinic receptor antagonist/long-acting beta2-adrenergic agonist (LAMA/LABA) and is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Incruse Ellipta (umeclidinium inhalation powder)
Incruse Ellipta (55 micrograms inhalation powder) is a long acting muscarinic receptor antagonist and is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.
Relvar Ellipta (fluticasone furoate/vilanterol inhalation powder)
Relvar 184/22 mcg Prescribing information
Relvar 92/22 mcg summary of product characteristics
Asthma
Relvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:
- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists.
- patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist.
COPD
Relvar Ellipta (92/22mcg inhalation powder) is indicated for the symptomatic treatment of adults with COPD with a FEV1<70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy.
Nucala (mepolizumab)
Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.
The recommended dose of Nucala is 100mg SC once every 4 weeks in adults and adolescents 12 years and older, available in pre-filled pen, pre-filled syringe or as a lyophilised powder.
The pre-filled formulations are not indicated in 6-11 year olds.
Seretide (salmeterol xinafoate / fluticasone propionate)
Seretide 50/100, 50/250, 50/500 Diskus
Prescribing information
Asthma
Seretide is indicated in the regular treatment of asthma where use of a combination product (long- acting β2 agonist and inhaled corticosteroid) is appropriate:
- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2 agonist
or
- patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist
Note: Seretide 50 microgram /100 microgram strength is not appropriate in adults and children with severe asthma.
Seretide 500/50 Diskus
Chronic Obstructive Pulmonary Disease (COPD)
Seretide is indicated for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
Seretide 25/50, 25/125, 25/250 Evohaler
Prescribing information
Asthma
Seretide is indicated in the regular treatment of asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate:
- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short- acting β2 agonist
or
- patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
